Indication sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.mechanism of action sorafenib interacts with multiple intracellular (craf, braf and mutant braf) and cell surface kinases (kit, flt-3, vegfr-2, vegfr-3, and pdgfr-k. several of these kinases are thought to be involved in angiogenesis, thus sorafenib reduces blood flow to the tumor. sorafenib is unique in targeting the raf/mek/erk pathway. by inhibiting these kinases, genetic transcription involving cell proliferation and angiogenesis is inhibited.